Yazarlar |
Dilek Akyüzlü
Ankara Üniversitesi, Türkiye |
Doç. Dr. Selin ÖZKAN KOTİLOĞLU
Kırşehir Ahi Evran Üniversitesi, Türkiye |
Ceylan Bal
Ankara Yıldırım Beyazıt Üniversitesi, Türkiye |
Gamze Avcıoğlu
Türkiye |
Şafak Yalçın Şahiner
Kütahya Sağlık Bilimleri Üniversitesi, Türkiye |
İsmail Volkan Şahiner
Kütahya Sağlık Bilimleri Üniversitesi, Türkiye |
Özet |
The study aimed to examine the genetic contribution to buprenorphine (BUP) treatment in individuals with opioid use disorder (OUD), with a specific focus on BDNF and OPRM1 genes. A total of 113 controls and 111 OUD patients receiving sublingual BUP/naloxone were enrolled. OPRM1 A118G and BDNF Val66Met polymorphisms were investigated by PCR-FRLP. Plasma BDNF and beta-endorphin levels were assessed by ELISA kits in both groups. Blood BUP levels were measured by LC-MS/MS and normalized with daily BUP dose (BUP/D). OPRM1 A118G and BDNF Val66Met polymorphisms didn't have an effect on plasma beta-endorphin and BDNF levels in OUD patients, respectively. Interestingly, OUD patients had significantly higher plasma BDNF and lower beta-endorphin levels compared to the controls (p < 0.001). A negative and significant correlation between plasma BUP/D and BDNF levels was found. Age onset of first use was associated with OPRM1 A118G polymorphism. The findings indicated that sublingual BUP/naloxone may increase plasma BDNF levels, but may decrease beta-endorphin levels in individuals with OUD. Plasma BDNF level seemed to be decreased in a BUP/D concentration-dependent manner. |
Anahtar Kelimeler |
Beta-endorphin | BDNF | Buprenorphine | Pharmacogenetics |
Makale Türü | Özgün Makale |
Makale Alt Türü | SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale |
Dergi Adı | ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY |
Dergi ISSN | 1382-6689 |
Dergi Tarandığı Indeksler | SCI-Expanded |
Dergi Grubu | Q1 |
Makale Dili | İngilizce |
Basım Tarihi | 10-2022 |
Cilt No | 95 |
Sayfalar | 103979 / |
Doi Numarası | 10.1016/j.etap.2022.103979 |
Makale Linki | http://dx.doi.org/10.1016/j.etap.2022.103979 |